Champions Oncology will be presenting data on it's preclinical model at the ongoing EORTC-NCI-AACR Symposium in Barcelona. The model proposes to help develop individualized treatments for patients.
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the delivery of two presentations at the 26th EORTC-NCI-AACR Symposium, held in , discussing the creation of an innovative TumorGraft model (ImmunoGraft) specific to immune-modulating therapeutics and benefits of Champions' TumorGrafts® in guiding clinical development strategy.
"There continues to be a need for improved models that enable researchers to better understand the clinical potential of therapeutics early in their development, ideally in the preclinical setting," said , Ph.D., chief scientific officer of Champions Oncology. "The findings presented at EORTC-NCI-AACR continue to demonstrate the advantages of our TumorGraft platform and our ability to create personalized mouse models for the exciting new class of immuno-oncology therapeutics. We look forward to presenting future case studies with our ImmunoGrafts at additional conferences in the year ahead."
Read the complete press release: http://prn.to/1F3F4M8